US Patent

US11083771 — Methods and compositions for the prevention or treatment of Barth Syndrome

Method of Use · Assigned to Stealth Biotherapeutics Corp · Expires 2034-02-28 · 8y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods of preventing or treating Barth Syndrome by administering an effective amount of an aromatic-cationic peptide to increase expression of TAZ1.

USPTO Abstract

The disclosure provides methods of preventing or treating Barth Syndrome in a mammalian subject, reducing risk factors associated with Barth Syndrome, and/or reducing the likelihood or severity of Barth Syndrome. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to increase expression of TAZ1 in subjects in need thereof.

Drugs covered by this patent

elamipretide-hydrochloride (ELAMIPRETIDE HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4277`	—	elamipretide-hydrochloride

Patent Metadata

Patent number: US11083771
Jurisdiction: US
Classification: Method of Use
Expires: 2034-02-28
Drug substance claim: No
Drug product claim: No
Assignee: Stealth Biotherapeutics Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.